Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vytorin Takes Low Road To Higher Ground: Lower LDL Is Key To Growth

Executive Summary

Schering-Plough sees positioning Vytorin as the preferred cholesterol therapy for achieving lower LDL levels as the key to future growth

You may also be interested in...



Rising Drug Use Stems From Changes In Clinical Guidelines – PhRMA Report

Increased use of drugs for high cholesterol is partly due to a paradigm shift from an initial approach of diet and exercise towards starting patients on drug therapy as the first course of action, according to a study on the increased use of medication for chronic conditions co-sponsored by the Pharmaceutical Research & Manufacturers of America and the Disease Management Association of America

Rising Drug Use Stems From Changes In Clinical Guidelines – PhRMA Report

Increased use of drugs for high cholesterol is partly due to a paradigm shift from an initial approach of diet and exercise towards starting patients on drug therapy as the first course of action, according to a study on the increased use of medication for chronic conditions co-sponsored by the Pharmaceutical Research & Manufacturers of America and the Disease Management Association of America

Joint Venture On The Rocks? Schering Looks To Compete With Partner Merck

Schering-Plough is exploring opportunities to add Zetia (ezetimibe) to an agent that would give the treatment an entrance into the growing HDL-cholesterol category

Related Content

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel